



EPA's Legislative Mandates (August 1996)

- Food Quality Protection Act (FQPA)
 - Must screen pesticides (including inerts) for estrogenic effects that may affect human health
 - Must use appropriate validated test systems or other scientifically relevant information
 - Can include other endocrine effects
- Safe Drinking Water Act (SDWA)
 - Can screen drinking water contaminants to which substantial numbers of persons are exposed

www.apt-pharmatox.com



The Endocrine Disrupter Screening Program

- Tier 1 to identify the potential of chemicals to interact with the estrogen, androgen and thyroid systems
- Tier 2 to identify and characterize the adverse effects resulting from that interaction and the exposure required to produce them

www.apt-pharmatox.con


Copyright @ 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved.




Tiered Hierarchical Framework for Hormonally Active Substances

- <u>Prioritization</u> of chemicals for screening and testing
- Screening assays (must be validated) to identify substances with hormonal activity & prioritize for more definitive testing
- Tests (must be validated) to characterize dose response of adverse effects mediated by the endocrine system

www.apt-pharmatox.con







Tier 2 Tests

- Protocols designed to evaluate <u>adverse health effects</u>
- Data to characterize nature, incidence, severity and <u>dose-response relationship of any adverse effects</u>
- Include <u>critical life stages</u>, <u>appropriate doses</u> & administer by <u>relevant route</u>
- Results supersede screening assay results
- 'Gold standard" multigeneration reproduction toxicity test

www.apt-pharmatox.con

Copyright @ 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved



Perspective: ER and AR Binding or Transcriptional Activation Assays

- Need systematic evaluation for inter-lab variability, sensitivity, reproducibility
- · Recommend standardization & validation of a single methodology
- A single protocol 'Gold Standard' needed by which to compare alternatives & for validation of QSAR
- Validation multiple labs, identical protocols, reference chemicals, GLP, data interpretation (pass / fail criteria)
- · ICCVAM review finding support this perspective

www.apt-pharmatox.com



Perspective: Tier 1 in vitro Steroidogenesis Assay

- · Confounding by cell toxicity is major limitation
- (Powlin et al. 1998) correctly detected only 4 of 9 substances
- To date standardization studies have not adequately addressed the cytotoxicity issue, the sliced testis assay validation has been discontinued, work on the H295R human adrenocortical carcinoma cell line continues
- It remains to be shown that the assay would be useful as a routine screen

www.apt-pharmatox.cor

Copyright © 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved.



Perspective: Tier 1 Uterotrophic & Hershberger

- Validation activities in progress via OECD (industry and research institute labs)
- Uterotrophic assay is essentially complete Peer review finalized, Test Guidelines under development
- · Hershberger assay is in last validation phase
- Industry supported chemical repository; approximately _ of the testing effort
- OECD program will result in guidelines that are internationally harmonized and accepted (therefore there will be mutual acceptance of data)

www.apt-pharmatox.com



Perspective: Low Priorities

Tier 1 Fish Gonadal Recrudescence Assay

Numerous practical difficulties - Not suitable as Tier 1 screen (endpoints affected by multiple factors that will be difficult to interpret)

Tier 1 Frog Metamorphosis Assay

This assay is <u>redundant</u> - other thyroid assays

Problems quantifying tadpole tail resorption; Prometamorphosis protocol under development

Lack of specificity (corticosterone and prolactin)

www.apt-pharmatox.cor

Copyright @ 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved.



Perspective: Tier 1 - Pubertal Assays

Considerable effort has been expended by EPA to assess performance

However --

- Endpoints are apical (*i.e.*, can be influenced by systemic toxicological effects unrelated to hormonal activity)
- Dose selection is critical many physiologic and toxicologic mechanisms can affect pubertal onset. Confounded in MTD is used.
- Inherent variability -- influences interpretation of "small" (< 2 days) changes in age at VP or PPS

www.apt-pharmatox.com





Perspective: Tier 1 - Pubertal Assays (continued)

What has not been done & is needed:

- Demonstration of dose-selection criteria
- "Negative controls" or "non-endocrine active" compounds run according to the dose selection criteria (& at MTD)
 - Are effects seen on these apical endpoints?
 - If so, what value is gained by the pubertals?
- What constitutes a "response" given the inherent variability of the endpoints?

www.apt-pharmatox.cor







Tier 1 Intact Adult Male Assay - Alternative to Pubertals

- Industry preferred approach that can be incorporated in a Tier 1 battery, utilizes fewer animals and is more cost effective than the EDSTAC-recommended battery
- Systemic evaluation > 20 reference substances representing diverse endocrine mechanisms

-Good sensitivity and specificity

www.apt-pharmatox.com



Comparison of the EDSTAC-Recommended and Alternative Tier 1 Screening Batteries


Alternate Screening Battery No. 1	Alternate Screening Battery No. 2
In vitro assays	In vitro assays
ER binding / transactivation	ER binding / transactivation
AR binding / transactivation	AR binding / transactivation
Placental Aromatase	Placental Aromatase
In vivo mammalian assays	In vivo mammalian assays
Uterotrohpic assay (5-day)	Uterotrophic assay (3-day)
Intact adult male	Pubertal male
	In vitro assays ER binding / transactivation AR binding / transactivation Placental Aromatase In vivo mammalian assays Uterotrohpic assay (5-day)




Comparison of the EDSTAC-Recommended and Alternative Tier 1 Screening Batteries

	\$6,050	×	X	
		X	Y	
	A7 500		^	X
	\$7,500	X	X	Х
10	\$6,850	X		
	\$8,175		X**	
36	\$14,500	X		
54	\$23,880	X		
60	\$44,700	X		
75	\$44,000		X	
45	\$67,900			Х
		160	111	81
		\$103,480	\$80,225	\$95,950
	36 54 60 75	10 \$6,850 \$8,175 36 \$14,500 54 \$23,880 60 \$44,700 75 \$44,000	10 \$6,850 X \$8,175 36 \$14,500 X 54 \$23,880 X 60 \$44,700 X 75 \$44,000 45 \$67,900	10 \$6,850 X \$8,175 X** 36 \$14,500 X 54 \$23,880 X 60 \$44,700 X 75 \$44,000 X 45 \$67,900

www.aableblaamatds.cor









Advantages: Intact Male Assay

- Comprehensive mode-of-action screen
 - Capable of screening multiple modes of action (E, A, T)
 - Run in parallel: uterotrohpic assay & in vitro binding assays
 - Redundancy of endpoints focus on mode of action
 - Tier 1 this assay provides mechanistic info that focuses direction of any further testing
- Design allows integration of new endpoints
 - Intact endocrine system
- · Cost effective because it integrates
 - Intact male assay replaces three assays in EDSTAC battery
 - Uses fewer animals than EDSTAC battery

www.apt-pharmatox.cor





Intact Ma	le Ass	say: F	inge	rprin	t of l	Jnkno	wns	
Endocrine Activity	ASG Unit (% body weight)	Thyroid (% body weight)	Test. (ng/ml)	E2 (pg/ml)	PRL (ng/ml)	LH & FSH (ng/ml)	TSH (ng/ml)	Τ ₄ (μg/dl)
Receptor Agonists Estrogen Receptor Androgen Receptor Progesterone Receptor	- /↓	- - -	↓ ↓ ↓	-/↓ ↑	†	- ∕↓ ↓	Ē	
Receptor Antagonists Estrogen Receptor Androgen Receptor Progesterone Receptor	_ _/↓		_ -⁄↑ -	<u>_</u>	-	-/↑ ↑ -/↑	Ξ	=
Steroid Biosynthesis Testosterone Synth. Inhib. 5α-Reductase Aromatase	↓ ↓	=	<u></u>	<u>-</u> ↓	<u>_</u>	↑ -/↑ -/↑	Ξ	- - -
Thyroid-Active Compounds	_	1	- /↓	_	→ /↑	14/-	1	1
Prolactin Pathway D-2 Receptor Modulators D-2 Agonist / Antagonist Broad Catechol Depletor	<u>-</u> ↑	- - -	$\frac{\downarrow}{\downarrow}$	<u>-</u> ↓	<u>_</u>	<u>-</u> ⁄↑	-	<u>-</u> ↓

HUSIAHI	ces Examined: 1	5 Day Intact Male Assa
Intact Male	Endocrine Active Compound	Endocrine Activity
+	17β-Estradiol	Estrogen receptor agonist (full or potent)
+	Coumestrol	Estrogen receptor agonist (weak or partial)
+	ICI-182,780	Estrogen receptor antagonist
+	Testosterone	Androgen receptor agonist
+	Flutamide	Androgen receptor antagonist (full or potent)
+	p,p'-DDE	Androgen receptor antagonist (weak or partial)
+	Vinclozolin	Androgen receptor antagonist (weak or partial)
+	Cyproterone Acetate	Androgen receptor antagonist (weak or partial)
+	Linuron	Androgen receptor antagonist (weak or partial)
+	Progesterone	Progesterone receptor agonist
+	Mifepristone (RU 486)	Progesterone receptor antagonist
-	Apomorphine	D ₂ receptor agonist
+	Haloperidol	D ₂ receptor antagonist
+	Reserpine	Dopamine depletor (broad catecholamine depletion)
+	Phenobarbital	Thyroid hormone excretion enhancer
+	Oxazepam	Thyroid hormone excretion enhancer
+	Propylthiouracil	Thyroid hormone synthesis inhibitor
+	Propylimidazole-2-thione (PTI)	Thyroid hormone synthesis inhibitor
+	Finasteride	5α-Reductase inhibitor
+	Ketoconazole	Testosterone biosynthesis inhibitor
+	Di-n-butyl phthalate	Steroid biosynthesis inhibitor (???)
+	Anastrozole	Aromatase inhibitor
+	Fedrozole	Aromatase inhibitor
+	Ammonium Perfluorooctanoate	Aromatase inhibitor

Perspective: Alternative Battery 1 is Superior					
Recommended Screening Battery	Alternate Screening Battery No. 1	Alternate Screening Battery No. 2			
In vitro assays	In vitro assays	In vitro assays			
ER binding / transactivation	ER binding / transactivation	ER binding / transactivation			
AR binding / transactivation	AR binding / transactivation	AR binding / transactivation			
Minced testis assay	Placental Aromatase	Placental Aromatase			
In vivo mammalian assays	<i>In vivo</i> mammalian assays	In vivo mammalian assays			
Uterotrophic assay (3-day)	Uterotrohpic assay (5-day)	Uterotrophic assay (3-day)			
Hershberger	Intact adult male	Pubertal male			
Pubertal female		_			



Purpose of Tier 2 Tests: Reminder

- Protocols designed to evaluate <u>adverse health effects</u>
- Data to characterize nature, incidence, severity and dose-response relationship of any adverse effects
- Include <u>critical life stages</u>, <u>appropriate doses</u> & administer by <u>relevant route</u>
- Results supersede screening assay results
- 'Gold standard" multigeneration reproduction toxicity test

www.apt-pharmatox.com

Copyright © 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved.



Overview: 2-Gen Rat Repro Study

- Current guideline protocol considered the definitive mammalian reproduction study for human health risk assessment
- Guideline was recently revised -- extensively -- to increase sensitivity to detect effects mediated by the endocrine system
 - sperm parameters, estrous cycling, developmental markers, more extensive parental histopathology, brain, spleen and thymus weights of weanlings, oocyte counting
- 5 to 8 years to revise and harmonize internationally 1998:U.S. EPA 2001:OECD, Japan
- A globally harmonized protocol is critical:
 - Animals Mutual Acceptance of Data
 - Resources Avoid ambiguous status

www.apt-pharmatox.com



Overview: 2-Gen Rat Repro Study

Additional endpoints have been suggested,

However -

- Any significant modifications must take into account international harmonization -- any changes to the guideline will affect it globally
- Already a complex study need to consider logistics and value of new endpoints

www.apt-pharmatox.con

Copyright @ 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved.



Overview: 2-Gen Rat Repro Study

- Some modifications could be demonstrated and validated in a relatively short period of time, examples:
 - enhanced clinical observations
 - thyroid weight & histopathology
 - whole brain weight and brain histology
- Major modifications would be problematic EPA has considered many suggestions for changes, including increasing number of retained pups

www.apt-pharmatox.com



Perspective: 2-Gen Rat Repro Study

- The existing multigenerational study is sensitive and effectively detects potential endocrine mediated adverse effects, including those that occur by estrogenic, androgenic, and thyroidogenic mechanisms, even those that occur at relatively low incidence.
- Recall that this is a multi-dose study (3 doses + control) and that
 the guidelines require the highest dose tested to induce some
 reproductive and/or systemic toxicity but not death or severe
 suffering
- Apical endpoints, adverse effects and dose response from Tier
 2 are used for risk assessment
 - · Tier1 assays do not evaluate adversity
 - Tier 2 results supersede Tier 1

www.apt-pharmatox.cor

Copyright @ 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved.



EPA is asking: Should a myriad of additional procedures and endpoints be added to & required in the 2-Gen?

A number of these proposed additional endpoints appear to be unnecessarily **redundant**

 If considered, each new measurement should be demonstrated to add value by increasing sensitivity, specificity, or reliability without impairing ability to assess endpoints currently required

www.apt-pharmatox.com



Concerns: Other Tier 2 Non-Mammalian Tests

- · Fish intermediate tier needed
- Fish lack of specificity of endpoints (FFLC)
- Avian inadequate triggers
- Mysid inappropriate species need to show plausible biological mechanism (such as estrogen specific receptor) otherwise inappropriate triggering criteria for the test

www.apt-pharmatox.cor


Copyright @ 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved.




Hazard ≠ Risk

- Screening assay data insufficient for risk characterization
- Risk characterization requires integration of testing data & exposure assessment:
 - Understanding of the hazard data endpoints & inferences/ relevance to humans
 - Dose-response
 - Exposure
- For example -- cannot assess risk with only RBA, uterotrophic/Hershberger

www.apt-pharmatox.com







Hazard Identification & Characterization Weight of Evidence Approach

Integration- relevant studies- assessment of overall adequacy and concordance of the data set:

- longer-term <u>definitive tests outweigh</u> or supercede <u>screening assays</u>
- higher quality studies are given more weight than lower quality studies
- substances with <u>inadequate data</u> sets are candidates for additional evaluation (case specific screening or testing)
- lack of concordance base decisions on preponderance of available data
- adequate & concordant data sets no additional testing, proceed to <u>risk assessment (& integrate exposure)</u> then risk management processes as appropriate

www.apt-pharmatox.con

Copyright @ 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved.



Implementation Timeline

- Late 2007: Mammalian screens (and possibly the wildlife screens) ready for use.
 - Before this can occur, OMB must approve the program
- Late 2009/early 2010: Tests validated

www.apt-pharmatox.com



Priority Setting for Chemicals

- EPA will require chemicals to be screened in batches
- First batch of chemicals Strategy released in 3Q 2005 (Fed. Reg. Sept. 27)
 - Prioritization and first list of chemicals based on exposure, not suspected endocrine disruption
 - Inert exposure based on HPV status (obviously not HPV as an inert)

www.apt-pharmatox.com

Copyright © 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved.



EPA's Current Approach to Priority Setting

- First list of compounds to be tested is planned to be released approximately 1 year before screens are ready
 - Letter to NRDC suggested 1Q 2005
 - Will have a comment period
- Requirement for screens (and tests)
 - Approximately 4Q 2006

www.apt-pharmatox.com



How Will Endocrine Testing Affect Inerts?

- EPA is developing data compensation and confidentiality rule, but little progress to date
- First list targeted for 50-100 pesticides and inerts
 - no decision on the split between pesticides and inerts
 - List likely to be out more than 1 year before anything can be done
- Important for inert and pesticide suppliers to work together for the good of both industries
 - Tier 1 screening studies estimated at ~\$250K/chemical. Tier 2 tests about \$1 million/chemical – protocols not well developed enough to predict accurately

www.apt-pharmatox.cor

Copyright @ 2005 Applied Pharmacology and Toxicology, Inc. All Rights Reserved



Issues with Screening "Today"

- What kind of screening is supposedly being done by some now?
 - Literature
 - Modeling
 - In vitro / in vivo
- Studies are not validated
- Relevance has not been established
- Apical endpoints are not likely to establish mechanism

www.apt-pharmatox.com